Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death ...

With underlying earnings growth of 7%, chemist owner and supplier EBOS Group is tapping healthy conditions in the sector.

Given the evidence that tophaceous MSU deposition is widespread and that hyperuricaemia now approaches epidemic proportions, we suspected that subclinical, microscopic deposition ... prostatectomies ...

A "Man Van" deployed in disadvantaged communities can help identify men at high risk for prostate cancer, according to a ...

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

Nearly one in eight men will be diagnosed with prostate cancer and, as a new UCSF study finds, significantly more of these ...

PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall recurrence and treatment failure. Patients with HRR-deficient metastatic ...